A Phase I/II Study Using Cabozantinib and Lanreotide as Treatment for Advanced Gastroenteropancreatic Neuroendocrine Tumors That Failed Molecular Targeted Therapies or Chemotherapy (SCALET)
Latest Information Update: 17 Jul 2024
At a glance
- Drugs Cabozantinib (Primary) ; Lanreotide (Primary)
- Indications Gastrointestinal cancer; Neuroendocrine tumours; Pancreatic cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms SCALET
- 05 Jul 2024 Planned End Date changed from 31 Dec 2025 to 31 Dec 2026.
- 05 Jul 2024 Planned primary completion date changed from 31 Aug 2025 to 31 Aug 2026.
- 05 Apr 2023 Status changed from not yet recruiting to recruiting.